Angel L Guerrero-Zotano

16PUBLICATIONS
180CO-AUTHORS
Predictive and prognostic markersMolecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Environmental epidemiology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (16)

|May 26, 2026
Sensitivity to endocrine therapy index predicts benefit from weekly adjuvant paclitaxel for hormone receptor-positive breast cancer in the GEICAM/9906 trial.

|Apr 06, 2026
Efficacy and Genomic Analysis of HER2-Mutant Metastatic Triple-Negative Breast Cancer Treated with Neratinib Alone or with Trastuzumab in the SUMMIT Basket Trial.

Komal Jhaveri, Lisa D Eli, Sara A Hurvitz

|Dec 22, 2025
Molecular and Clinical Analyses of Gene Fusions Identify Therapeutic Targets in Paired Primary and Metastatic Breast Cancer from the AURORA Program (BIG 14-01).

Chiara Biagioni, Danai Fimereli, Alexandre Irrthum

|Dec 12, 2025
Neoadjuvant Abemaciclib plus Letrozole Versus Chemotherapy in Patients with HR+/HER2- Highly Proliferative Breast Cancer.

Miguel Martín, Ángel L Guerrero-Zotano, María E Pérez-López

|Oct 29, 2025
A Retrospective Observational Study of Extended Adjuvant Neratinib for HER2-Positive Early-Stage Breast Cancer in a European Early Access Program.

Marija Križić, Tajana Silovski, Griet Hoste

|Oct 29, 2025
The Prognostic and Predictive Impact of ctDNA Levels in Patients with Advanced Breast Cancer Enrolled on the plasmaMATCH Trial.

Iseult M Browne, Javier Pascual, Rosalind J Cutts

Pageof 3

Frequent Collaborators

7 joint publications

Miguel Martin

6 joint publications

Manuel Ruiz-Borrego

5 joint publications

Jesus Herranz

4 joint publications

Jose Ángel García-Sáenz